OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Wainberg on Optimal Dosing With Regorafenib in CRC

April 19th 2021

Zev A. Wainberg, MD, discusses optimal dosing with regorafenib in colorectal cancer.

Dr. Barrientos on the Shift Away From Chemoimmunotherapy in CLL

April 19th 2021

Jacqueline Claudia Barrientos, MD, MS, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Goy on the Potential Utility of Liso-Cel in MCL

April 19th 2021

Andre H. Goy, MD, discusses the potential utility of lisocabtagene maraleucel in mantle cell lymphoma.

Dr. Burgess on Treatment Considerations for PARP Inhibitors in Prostate Cancer

April 16th 2021

Earle Burgess, MD, discusses treatment considerations for PARP inhibitor use in patients with prostate cancer.

Dr. Meisel the Potential Utility of CDK4/6 Inhibitors in HER2+ Breast Cancer

April 16th 2021

Jane L. Meisel, MD, discusses the potential utility of CDK4/6 inhibitors in HER2-positive metastatic breast cancer.

Dr. Bhave on Promising Combination Strategies in TNBC

April 16th 2021

Manali Bhave, MD, discusses promising combination strategies in triple-negative breast cancer.

Dr. Usmani on Optimizing Treatment Selection in Relapsed/Refractory Multiple Myeloma

April 16th 2021

Saad Z. Usmani, MD, FACP, discusses optimizing treatment selection in relapsed/refractory multiple myeloma.

Dr. Au on Antibody Responses to COVID-19 Observed in Patients With Cancer

April 15th 2021

Lewis Au, MBBS, BMedSci, FRACP, discusses antibody responses to COVID-19 observed in patients with cancer.

Dr. Verstovsek on the Potential Utility of Luspatercept in Myelofibrosis

April 15th 2021

Srdan Verstovsek, MD, PhD, discusses the potential clinical utility of luspatercept-aamt in myelofibrosis.

Dr. O’Malley on the Results of the KEYNOTE-775 Trial in Endometrial Cancer

April 15th 2021

David M. O'Malley, MD, discusses the results of the phase 3 KEYNOTE-775 trial in advanced endometrial cancer.

Dr. Saba on Unique Characteristics of Nasopharyngeal Carcinoma

April 15th 2021

Nabil F. Saba, MD, FACP, discusses some of the unique characteristics of nasopharyngeal carcinoma.

Dr. Rogers on the Safety Profile of Ianalumab/Ibrutinib in CLL

April 14th 2021

Kerry A. Rogers, MD, discusses the safety profile of the combination of ianalumab plus ibrutinib, in patients with chronic lymphocytic leukemia.

Dr. Tagawa on the FDA Approval of Sacituzumab Govitecan in Advanced Urothelial Carcinoma

April 14th 2021

Scott T. Tagawa, MD, MS, FACP, discusses the FDA approval of sacituzumab govitecan-hziy in advanced urothelial carcinoma.

Dr. Strickler on the Need for Chemotherapy-Free Options in Third-Line Metastatic CRC

April 14th 2021

John H. Strickler, MD, discusses the need for additional chemotherapy-free options in the third-line setting for patients with metastatic colorectal cancer.

Dr. Atkins on the Role of Adjuvant Chemoradiation in Gastric Cancer

April 14th 2021

Katelyn M. Atkins, MD, PhD, discusses the role of adjuvant chemoradiation therapy in gastric cancer.

Dr. Costa on the Evolving Treatment Paradigm in Newly Diagnosed Multiple Myeloma

April 14th 2021

Luciano J. Costa, MD, PhD, discusses the evolving treatment paradigm in newly diagnosed multiple myeloma.

Dr. Till on Data With Liso-Cel Vs Other Products Under Examination in MCL

April 14th 2021

Brian Till, MD, discusses the safety and efficacy of lisocabtagene maraleucel compared with other products under exploration in patients with mantle cell lymphoma.

Dr. del Rio on Remaining Questions With the COVID-19 Vaccines

April 13th 2021

Carlos del Rio, MD, discusses remaining questions with the COVID-19 vaccines.

Dr. Vij on the Potential of CELMoDs in Relapsed/Refractory Multiple Myeloma

April 13th 2021

Ravi Vij, MD, MBA, discusses the potential of cereblon E3 ligase modulators in relapsed/refractory multiple myeloma.

Dr. Coveler on the Toxicity Profile of NUC-3373 in Metastatic CRC

April 13th 2021

Andrew Coveler, MD, discusses the toxicity profile of NUC-3373 in metastatic colorectal cancer.